about
Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agentRecycling existing drugs for cancer therapy: delivering low cost cancer careThe Repurposing Drugs in Oncology (ReDO) Project.Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent.Primed for cancer: Li Fraumeni Syndrome and the pre-cancerous nicheRepurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agentRepurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agentNext generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai.Emergent properties of a computational model of tumour growth.Repurposing Drugs in Oncology (ReDO)-nitroglycerin as an anti-cancer agent.Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agentRepurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agentThe wisdom of crowds and the repurposing of artesunate as an anticancer drug.Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents.Repurposing drugs in your medicine cabinet: untapped opportunities for cancer therapy?Perioperative therapies - Enhancing the impact of cancer surgery with repurposed drugs.Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents.“Hard” Drug Repurposing for Precision Oncology: The Missing Link?ReDO_DB: the repurposing drugs in oncology databaseA Computational Model of Tumor Growth and AnakoinosisScientific advice - is drug repurposing missing a trick?Repurposing Drugs in Oncology: Next StepsNew uses for old drugsOn paranoid parentsLung Cancer Survival Gains: Contributions of Academia and IndustryPropranolol and breast cancer-a work in progressJournal retractions in oncology: a bibliometric studyBiased by design? Clinical trials and patient benefit in oncologyEditorial: Drug RepurposingPerioperative Therapies-Using Repurposed Drugs to Improve Cancer Surgery Outcomes
P50
Q33893928-6FADE11C-56CE-47F2-A917-AFCFE5B279EAQ33893944-067718D1-6C6F-4FB1-A133-E6EA5AB09DF9Q33893949-080F48B5-D47B-435E-961F-DC761AB5480BQ34474583-ED48AEEC-8525-48F2-9CF8-C920B26C5772Q35717532-BD3A7527-37CB-4767-B801-9521D79F02ABQ36483712-E40E78A8-4383-4FA1-A4A1-C6C1EB2A95F4Q37404693-47D4B223-671F-4D87-B497-2C1D8A124BF9Q37458763-C7A51F39-B443-4796-9D1D-671C6DAD1F85Q39603486-B810F043-CA56-4977-8412-239DE3CF6371Q40468319-50648A22-95E2-4D10-89AF-43599245F50AQ41327770-9FEA381B-4827-4A03-A65C-00559E283709Q41668110-3593151E-6EFA-4B43-8842-B8862CBDDAC5Q41912530-756B86A1-2EF3-4DB8-B2B4-EF9865FD700BQ47162451-A2943C3E-7106-4344-ABD1-B74185467929Q48632194-46ACEE0A-8404-4FFF-984B-6AA8EE69EF86Q50013581-F8DE44D5-FFDA-415C-8F53-C5CA94C6E1CBQ55247585-94A0E471-C82A-4D1C-A131-7274B8B8E4E8Q55371416-BC45E17A-6BAE-43C6-AB9D-8E24EEBADC30Q61450929-366FDB5F-A827-44B3-AC0C-1255C7D7E823Q64118821-5235E1E9-3928-401E-A62C-66A011A174C0Q88128202-A23C7788-AF21-4AD1-9C0D-F09C7FFF6835Q88693139-2A011670-1E69-4349-B029-BDCABFB09868Q89266655-107FEDF4-0807-4B86-AA50-CCB6099F24FEQ89917829-F7E34B2D-83A4-47DB-97C7-682D5DF30E00Q90329100-D39FBB47-A7BA-4760-B740-BB82FB3432AFQ90402402-B8852187-296B-4BC3-AE2C-81BC30E981B4Q90978831-B93D2F51-7591-40E5-803F-EC3B1CEC9C58Q91862254-B96BCF47-2D93-4B7D-9AA7-D1F44896A576Q92111225-6D143801-1E8A-438B-B694-76EEEB74EF33Q92523254-CCFD1723-E988-4B76-8F5D-68BB3EA367A6
P50
description
investigador
@es
researcher
@en
name
Pan Pantziarka
@en
type
label
Pan Pantziarka
@en
prefLabel
Pan Pantziarka
@en
P31
P496
0000-0002-4676-7835